GSK And Singapore's Economic Development Board Finance Asian Public Health Research Through Public-Private Fund
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - The National University of Singapore has set up an initiative to advance public health and healthcare delivery in Asia. The 10-year initiative will be funded with S$17 million ($12.3 million) from the GSK-EDB Trust Fund, a joint fund created by GlaxoSmithKline and Singapore's Economic Development Board
You may also be interested in...
Singapore’s Bio*One Capital Eyes Services, Data and Devices In Investment Push: An Interview With PharmAsia News
The biomedical investment arm of Singapore’s state-run investment firm EDBI, gives PharmAsia News insight into where its next round of investments are aimed.
Large Section Of Vietnam's Populace Lacks Access to Affordable Essential Drugs - University And Health Ministry Researchers
SHANGHAI - While price levels on drugs in Vietnam are relatively high when compared with average incomes nationwide, the government has been moving to control prices, in part to improve access to essential medicines
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets. Since then, GSK's APJEM R&D - Asia Pacific, Japan, and Emerging Markets - has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't. Macrae's lean eight-person team has, in its approach to companies, said that while GSK is looking for later-stage molecules, the group is not opposed to licensing a compound for Asia while its partners pursue Western deals with another company (PharmAsia News, April 9, 2009).